Recurrent Study Design
In recurrent GBM,
The efficacy and safety of Optune Gio monotherapy were compared with physician's choice of chemotherapy*
EF-11 phase 3 pivotal trial—Optune Gio vs physician’s choice of chemotherapy, including bevacizumab1
*Therapy options were the physician's best choice for chemotherapy. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.
- Approximately 20% of patients in each EF-11 treatment arm had failed a prior bevacizumab-containing regimen1
Key efficacy endpointsKey efficacy endpoints1,2
- Primary endpoint
- OS
- Secondary endpoints
- PFS
- 1-year survival
- Median time to progression
- Radiological response rates
- QoL
Key inclusion criteria1,2
- Not a candidate for further radiotherapy or additional resection of residual tumor
- Subjects with disease progression (by McDonald criteria, ie, >25% or new lesion) documented by CT or MRI within 4 weeks prior to enrollment
- KPS ≥70
Key exclusion criteria1,2
- Significant comorbidities within 4 weeks prior to enrollment
- Surgery for recurrence within 4 weeks
- Infratentorial tumor
- Prior radiation or chemotherapy in the past 4 weeks
- Implanted pacemaker, defibrillator, or deep brain stimulator, or documented clinically significant arrhythmias
EF-11: Key baseline characteristics1,2
Intent to treat (ITT) population
Single agent or combination regimens
Learn how to integrate Optune Gio into your practice
†Multiple listings possible, some agents given in combination.
BCNU, carmustine; CCNU, lomustine; CT, computed tomography; GBM, glioblastoma; KPS, Karnofsky Performance Score; MRI, magnetic resonance imaging; OS, overall survival; PCV, procarbazine + lomustine + vincristine; PFS, progression-free survival; PFS6, progression-free survival at 6 months; QoL, quality of life.
References: 1. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202. 2. Optune Instructions for Use. Novocure 2019. 3. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Supplemenary table 1. Accessed October 18, 2023. Eur J Cancer. 2012;48(14):2192-2202. https://www.ejcancer.com/article/S0959-8049(12)00352-8/fulltext#supplementaryMaterial